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The principle ofX-ray fluorescence (XRF)
is the use ofphotons to fluoresce atoms of
the element of interest. Fluoresced atoms
can then emit X-rays ofenergies specific to
that element. The number ofX-rays is pro-
portional to the amount of the element
present in the sample. Both 7-rays from
radioisotopes and X-rays from a generator
have been used as the fluorescing photons
in bone lead measurement systems. The
major difference between methods is
whether they fluoresce the K-shell or the L-
shell electrons of lead. Two of the three
reported methods fluoresce K-shell elec-
trons. The difference between K and L lead
X-rays is their energy: L X-rays range in
energy from 9.2 to 12.6 keV; K X-rays
range from 72.8 to 87.3 keV. The energy
of the X-rays determines their ability to
overcome the effects of attenuation and
escape from the body for detection.
Attenuation is one of the most impor-
tant factors in any XRF measurement
method because both the fluorescing pho-
tons (produced by whichever method) and
the fluoresced X-rays (be they K- or L-
shell) are attenuated by whatever material
they pass through. In bone lead measure-
ments, the tissue overlying the bone site
and within the bone itself are the regions
ofprincipal concern. Attenuation is charac-
terized by the mass attenuation coefficient
which depends on the composition of the
material and the energy ofthe photon. For
a particular substance and particular pho-
ton energy, the mass attenuation coeffi-
cient can be used to obtain the more readi-
ly understandable quantity of the "mean
free path." The mean free path is, as the
name suggests, the average distance trav-
eled by a photon before undergoing some
form of interaction. In bone lead measure-
ments, the interaction is usually a Comp-
ton scattering event, which can reduce the
energy of the photon. Compton scattering
is undesirable for two reasons. First, the
energy of a fluorescing photon is reduced;
the resulting scattered photon may no
longer have sufficient energy to interact
with a lead atom to produce an X-ray.
Such scattered photons produce a relatively
intense background in the energy spectrum
on which lead quantitation is based and are
the main limitation on measurement preci-
sion. Second, if a fluoresced X-ray is
Compton scattered, it no longer has one of
the characteristic lead energies and thus
contributes further to the background
instead ofthe signal.
In considering attenuation, we broach
one of the fundamental differences be-
tween K and L XRF: the difference in the
volume ofbone sampled. In both K and L
XRF, attenuation of both fluorescing and
fluoresced photons needs to be considered
in a rigorous analysis. However, for our
purposes a simple illustration will suffice.
For the L XRF system, we will ignore
attenuation ofthe fluorescing photons and
consider only attenuation ofthe La X-rays
(10.55 keV) because this is the larger
effect. The mean free path of these X-rays
is 1.5 mm in soft tissue and 0.2 mm in
bone. For the K XRF systems that use the
88.035 keV y-ray from 109Cd, the com-
bined effects of attenuation on a fluoresc-
ing y-ray and a Kai X-ray (75.0 keV) give
a mean free path of 19.0 mm in soft tissue
and 9.0 mm in bone. Ignoring attenuation
of the L XRF fluorescing photons may
underestimate the difference between K
and L XRF, but the underestimation is not
great. Another illustration of the effect of
attenuation is given by the depth at which
the sensitivity ofa system falls to a certain
level, as calculated by Thomas (1): for L
XRF, 30% sensitivity occurs 1.3 mm into
bone, for K XRF the distance is approxi-
mately 25 mm. Thus, lead La X-rays have
difficulty escaping from the body, and the
regions ofbone lead beyond approximately
2 mm are not sampled.
Similarities and Differences of
Practical Measurement
Systems
The literature on the measurement oftrace
and minor elements in vivo has been
reviewed elsewhere (2,3). The reviews and
our previous work (4) describe the depen-
dence of the sensitivity of XRF measure-
ment systems on the fluorescing source
energy and on source-target-detector
geometry. In vivo measurements oflead in
bone have been performed with three XRF
methods: two fluorescing the K-shell elec-
trons of lead (57Co in a 900 geometry and
9Cd in a backscatter geometry) and one
reVie othhuaboeld ties per-
fo.rm.ed.:.todte;age and of some ..... :: :.: ... .:
issues su gfuture plicaion ofthe
memesk RDo wedc ones;Lea X-ray, X
102:172...177(1994)Y. X~.
.. ........... . ~ .,..;..... ...... ...........
.. ... .. .. ..
fluorescing the L-shell electrons (using 125I
or an X-raygenerator).
In addition to the fluorescing source,
the components of an XRF measurement
system consist of a radiation detector [of
the type most suited to the energy ofradia-
tion under study; Ge for K XRF, Si(Li) for
L XRF], preamplifier, amplifier, analog-to-
digital converter, multichannel analyzer,
and computer for data storage and analy-
sis. All bone lead measurements are nonin-
vasive; the subject must sit in a chair and
have the measurement system moved into
place. 109Cd K XRF measurements are
typically performed for approximately 30
min, L XRF measurements for 16 min. A
recent paper (5) shows a practical measure-
ment being made with a 09Cd K XRF sys-
tem. Each system is transportable, allow-
ing mobile laboratory facilities to be estab-
lished.
The first in vivo measurements were
performed at the University of Lund,
Sweden, using 57Co as the fluorescing
source. The measurement site was the pha-
lanx, and the achieved detection limit
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(defined as an X-ray peak area equal to
three times the standard deviation of the
underlying background counts) was ap-
proximately 20 pg Pb/g bone wet weight,
for an effective dose equivalent (using
superseded nomenclature) of approxi-
mately 0.1 pSv (6-8). The same method
has been adopted by the Queensland
University of Technology, Australia, also
measuring the phalanx (9), and was inde-
pendently developed at the University of
Pennsylvania, where the measurement sites
have been teeth, wrist, and temple (10,11).
The development of L XRF systems to
measure lead in bone has been conducted
by Brookhaven National Laboratory
(12-14). Use of the L XRF method has
not yet been reported other than from the
medical center that collaborated on the
original development. However, our labo-
ratories are engaged in the development of
this technique.
The third XRF method employs the
88.035 keV y-rays from 109Cd to fluoresce
the K shell X-rays and adopts a backscatter
geometry. The third method was devel-
oped at the University of Birmingham,
England, and has been adopted by other
research groups: Singleton Hospital,
Swansea, Wales (15), Brookhaven Na-
tional Laboratory (16), and the Institute of
Occupational Health, Vantaa, Finland
(17,18). The 109Cd method has also been
developed commercially (19). The com-
mercial system was adopted by the Uni-
versity of Pittsburgh (20), Harvard School
of Public Health (21-23), and the Uni-
versity of California, San Francisco (24).
In collaboration with the authors, most
groups with commercial systems are in the
process of improving them via hardware
retrofitting and adoption of alternative
methods ofcomputational peak extraction.
Recent improvements to the 109Cd method
have been reported by McMaster Uni-
versity (25,26), the University ofMaryland
(27,28), and Queen Elizabeth Medical
Center, Birmingham, UK (29,30). The
improvements result principally from using
larger-volume detectors (in conjunction
with sources with a high activity per unit
area) and faster spectroscopy electronics.
Additional 9Cd K XRF measurement
systems are present at Mount Sinai Med-
ical Center, New York, and the University
of Cincinnati; to date neither institution
has published a report. The reasons for
such widespread use of the 109Cd K XRF
method lie in its methodological advan-
tages, which are described throughout this
paper.
Intercomparison of Methods
The two K XRF methods have been used
in a collaborative study (31), where their
performances were compared. The 109Cd
method gave better precision than the
57Co method (10 jig Pb/g bone mineral
versus 50 pg Pb/g bone mineral, respec-
tively), but also delivered a higher effective
dose equivalent (0.1 pSv versus 2.1 pSv,
respectively) (3,32). However, the reported
doses from the two systems are not calcu-
lated according to the most recent guide-
lines (see below).
Radiation Dose
All bone lead measurements use radiation,
making the radiation dose and its conse-
quent risk important concerns. The dose
delivered by all bone lead measurement
methods is small. Nevertheless, full radio-
dosimetric analyses of the 109Cd K XRF
and L XRF methods have been performed,
using the current methods ofdose calcula-
tion. The 109Cd K XRF study (20) indicat-
ed an effective dose to a 1-year-old child,
an adult male, and an adult female of 1.1
pSv, 34 nSv, and 38 nSv, respectively. The
L XRF dosimetry for measurements of
pregnant women was the focus of a paper
by Kalef-Ezra et al. (33). A full analysis of
the L XRF system has also been published
(34), then corrected and updated to the
most recent guidelines (35). The most
recent paper (35) indicated an effective
dose to a 1-year-old child more than twice
as great as that from a 109Cd K XRF mea-
surement and a dose to an adult approxi-
mately eight times greater. The dose deliv-
ered to a conceptus is lower for L XRF, by
a factor of approximately 20. The differ-
ences between the doses of the two meth-
ods are less important than their magni-
tudes: for 109Cd K XRF, the effective dose
for a 1-year-old child is equivalent to
approximately 3 hr of the average effective
dose arising from background radiation
(36); the additional risk ofa cancer mortal-
ity (excluding leukemia) is approximately 1
in 10 million (20). From these facts, it is
clear that radiation risk should not be a
limiting factor in using either method.
Precision
There is an ever-increasing improvement
in the performance ofnuclear spectroscopy
components, which is partly responsible
for the improvements in detection limit
reported over recent years. Improvements
in measurement precision continue in
many laboratories. Currently quoted preci-
sions are in the range of 4-10 jig Pb/g
bone, where bone, for L XRF, indicates
wet weight, and, for K XRF, indicates
bone mineral. For an adult tibia, conver-
sion between the two units requires multi-
plication of the wet weight value by 1.8;
for other bones, the conversion factor is
greater. Precision (for all methods) de-
pends on the amount of tissue overlying
the bone: the greater the thickness of tis-
sue, the worse the precision. For example,
in comparing 3 mm and 6 mm ofoverly-
ing soft tissue, 109Cd K XRF precision
worsens by 5%, L XRF precision worsens
by 49%. The precision of the L XRF
method is affected by the heavy attenua-
tion of the lead L X-rays. In L XRF, the
number ofobserved X-ray counts is adjust-
ed to the number of counts that would
have been observed if the subject had pos-
sessed 5 mm of overlying tissue; i.e., the
number of X-rays is scaled to correct for
the effects ofattenuation.
The number of X-ray counts sets a
limit on precision, but the method ofcon-
version from counts to concentration is
also important. Ultrasound measurement
of overlying tissue thickness is required
with the L XRF method, introducing a
further uncertainty arising from the preci-
sion of the ultrasound measurement. The
precision of ultrasound measurement was
reported by the L XRF pioneers to be 0.3
mm (37), resulting in an uncertainty of
approximately 13% in the factor used to
convert a measurement from counts to
concentration. The uncertainty from ultra-
sound measurement is then added (in
quadrature) to that arising from counting
statistics. For low bone lead levels, the
ultrasound uncertainty is minor; but for
high bone lead concentrations, it sets the
lower limit to total measurement uncer-
tainty. Table 1 shows the L XRF uncer-
tainty (in terms of wet weight bone) for
three different "true" bone lead concentra-
tions. For each entry in Table 1, the uncer-
tainty from counting statistics is a constant
± pg Pb/g bone wet weight. (Note that
counting statistics uncertainty is deter-
mined largely by the magnitude of the
spectral background, rather than the X-ray
peak.) The effect ofultrasound uncertainty
on overall uncertainty is clear. For compar-
ison, Table 1 also shows the effect of
increasing bone lead concentration on
109Cd K XRF precision. In the 109Cd
method, conversion from counts to bone
Table 1. Effect of increasing bone lead concentration on the precision of luCd K XRF and LXRF measure-
ments
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lead concentration is performed by nor-
malization of the lead X-ray signal to the
elastically scattered photons appearing in
the spectrum. The elastic scatter peak is
much more prominent than the X-ray
peaks and can, therefore, be determined
with much greater precision, thus worsen-
ing the total precision by an insignificant
amount.
Accuracy
The conversion from counts to bone lead
concentration is usually performed via ref-
erence to calibration standards. Standards
for the 109Cd K XRF are made from lead-
doped plaster of Paris. Plaster produces an
elastic scatter peak similar to that seen dur-
ing a measurement of bone. Correction
from pg/g plaster to mg/g bone mineral
simply requires multiplication by a con-
stant. The value of the constant depends
on the elemental composition of plaster
and bone and (weakly within the range of
angles considered) on the scattering angle
used. Within current K XRF measurement
precisions, it is possible to produce accu-
rate standards for the K XRF methods.
Recent discussions of XRF practitioners
have covered the need for a single set of
measurement standards to be used by all
research groups (38). Because ofthe differ-
ent volumes of bone sampled, the fabrica-
tion of such standards may prove to be
both difficult and expensive.
Accuracy is also affected by assump-
tions about the distribution of lead in
bone, viz., that the lead concentration of
soft tissue is zero and that lead is homoge-
neously distributed in bone over the scale
being considered. The first part of the
assumption would benefit from examina-
tion, as both methods are capable of sam-
pling lead in the soft tissue overlying the
bone. This is particularly true for the L
XRF method, which would be very sensi-
tive to soft tissue lead and/or lead on the
skin. The second assumption has data both
to support and to qualify it. Wittmers et al.
(39_ indicate that bone lead concentration
is relatively uniform along the length ofthe
tibia, which is the primary measurement
site for 109Cd K XRF and the only mea-
surement site for L XRF. However, there
are also data indicating the heterogeneity
ofbone lead concentration with increasing
depth into bone (40-43). Areas of bone
lead concentration a few times greater than
the average level are seen on a scale of<0.1
mm. The implications of such regions of
unrepresentative lead concentration de-
pend on the spatial resolution ofthe mea-
surement system. Recalling that the mean
free path for fluorescing 7-rays and the
principal lead KX-rag is 9.0 mm in bone,
it is clear that the Cd K XRF method
integrates over the region ofheterogeneity.
The same is true for the 57Co K XRF
method. The mean free path for the prin-
cipal lead L X-ray is 0.22 mm in bone,
making it particularly sensitive to the het-
erogeneity in bone lead concentration.
Validation
Both K and L XRF methods have been val-
idated, in each case by comparison be-
tween XRF and atomic absorption spec-
trophotometry (AAS). Validation of '09Cd
K XRF was reported by Somervaille et al.
(44). This was an indirect comparison; i.e.,
bare-bone samples had a core removed for
AAS analysis before delivery for 109Cd K
XRF measurement. XRF and AAS meth-
ods were independently calibrated. Paired
analysis between AAS and 109Cd K XRF
was conducted on 80 samples: bones from
tibia sections, tibia fragments, calcaneus,
and metatarsals. The mean difference
between 109Cd K XRF and AAS measure-
ments was <0.1 pg Pb/g bone mineral. The
largest difference found was for a subset of
three tibia fragments, which exhibited a
difference of approximately 5 pg Pb/g
bone mineral (45). It should be noted that
AAS and 109Cd K XRF sample different
average bone masses: 20 mg and 10-15 g,
respectively. Validation of bare-bone mea-
surements was thus produced. Validation
of intact bone measurements relies on fur-
ther experiments which indicate that the
accuracy ofthe elastic scatter normalization
process is independent of the amount of
tissue overlying the bone (46). More limit-
ed data for direct validation of 109Cd K
XRF for intact, amputated limbs has been
reported by Hu et al. (21), work that
appears to confirm the accuracy of the
method. Other direct comparison was pro-
vided by measurements made on autopsy
samples from a subject who had previous
57Co K XRF bone lead measurements
(8,4?). Once again, these data appear to
confirm the accuracy of the K XRF
method employed. However, the data are
few, there is a time lapse between XRF and
AAS measurements and, as the subject was
elderly, lead and calcium metabolism could
have been changing.
The L XRF method was validated
using amputated, intact, human limbs. L
XRF measurements were performed first
with the overlying tissue intact, and then
removed. Bone samples were then inde-
pendently measured by AAS (14). Ten
amputated limbs were used; the results
from one were excluded from the final
analysis because of an (assumed) incorrect
evaluation of overlying tissue thickness.
Two further samples were included once
their measurement results had been adjust-
ed; adjustment was required after suspect-
ed positioning errors. No further problems
with tissue thickness measurement and/or
with positioning errors have been reported,
though presumably the problems are no
less with people than with amputated
limbs. Positioning and movement prob-
lems for small children have been alleviated
by sedation. This practice is not necessary
for the other XRF methods. A final
methodological complication is that the
validation data of the L XRF method also
serve as its calibration data. Full statistical
independence requires separate samples for
calibration and validation.
Robustness and Adaptability
In the 109Cd K XRF method, the lead X-
rays are normalized to the elastic scatter
peak. Normalization yields a measurement
accuracy that is independent of several
potential confounders: fluorescing source
to subject distance, overlying tissue thick-
ness, bone size, bone shape, bone geome-
try, bone density, nongross differences in
interindividual positioning ofthe measure-
ment apparatus, and minor patient move-
ment. To a greater or lesser extent, the
other XRF methods depend onall of these
factors. The ability of the 109Cd K XRF
method to perform measurements at sever-
al different bone sites and to make mean-
ingful comparisons of the results obtained
was illustrated by the Birmingham group
in an extensive series ofstudies and collab-
orations with groups in Sweden and Fin-
land. Together, the studies report the mea-
surement oflead in tibia, calcaneus, wrist,
skull, and sternum (18,31,44,46,48-53).
Human Studies Using XRF
L XRF measurements have been principal-
ly performed on children, although there
have been some measurements of occupa-
tionally exposed adults (13,54). In chil-
dren, L XRF measurements have been
compared to the outcome ofa provocative
EDTA chelation test, with a view to using
the noninvasive and rapid L XRF test as a
replacement for the time-consuming chela-
tion test. Methods are presented in the
original paper (55); corrected results were
republished (56). When the outcome of
the EDTA test, bone lead, and blood lead
were all used as categorical variables (i.e.,
"raised" or "not raised"), blood lead and
bone lead exhibited approximately equal
power in their abilities to predict the out-
come of the EDTA test. In combination,
blood lead and bone lead could predict the
outcome of the EDTA test in approxi-
mately 90% of the 59 cases. In the same
children, blood lead correlated slightly
more strongly with EDTA lead than did
bone lead (Pearson correlation coefficients
of0.701 and 0.472, respectively). The dif-
ference between the two was not highly
significant (p>>5%). The same data were
subsequently presented in a more complete
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report (5), an earlier version of which
(58) contains printing errors and should be
disregarded.
In a study of L XRF and chelation in
adults, a correlation between L XRF bone
lead and chelated lead was also ob-
served (13). The adult L XRF data were
reported to be broadly consistent with the
findings ofJones et al. (16), who used a
109Cd K XRF method. In contrast, Schutz
et al. (59), studying chelatable lead after
administration of penicillamine, found no
relationship between chelatable lead and
57Co K XRF lead measured in finger bone
but did find a relationship between chelat-
able lead and vertebral bone biopsies. The
data of Schutz et al. clearly show that fin-
ger bone lead and penicillamine-chelatable
lead are closely related only when subjects
are in the same exposure status. Retired
workers show a much higher ratio ofbone
lead to chelated lead than active workers.
The inference is that whole bone lead, as
measured by K XRF, samples a different
and longer-term lead compartment than
that sampled by the provocative chelation
test. More recently, a collaborative project
between the groups at Birmingham (using
109Cd K XRF to measure tibia and calca-
neus) and Malmo/Lund (using 57Co K
XRF to measure phalanx) studied bone
lead over a course of EDTA chelation in
20 workers. They found no evidence of
statistical significance for a decrease in
bone lead measurements of either tibia or
calcaneus over the course of chelation.
None ofthe bone sites correlated well with
EDTA-chelated lead, although they all cor-
related well with each other. The strongest
indicator of24-hr chelated lead was found
to be prechelation blood lead (r = 0.86;
p<0.0001) (60). The report concluded
with support for the argument that
EDTA-chelated urinary lead primarily
reflects the blood and soft tissue lead pools,
rather than the total body burden. These
findings invite further research, as they
have important implications for under-
standing studies of blood lead, bone lead,
and chelated lead.
Historically, studies with K XRF
109Cd or 57Co) have concentrated on
adult male lead workers (8,18,31,46,47,
49,51,52,61-64), although there have
been measurements of other groups: fe-
males, lead-toxic patients and environmen-
tally exposed subjects (21,46,65). Indus-
trially exposed subjects with recorded
blood lead histories have provided a sec-
ondary, indirect validation of the K XRF
methods. Integrating the area under a
blood lead-versus-time curve yields a
cumulative blood lead index, which is a
surrogate for long-term lead exposure. A
strong relationship between K XRF and
cumulative blood lead index has been
found for both 57Co KXRF (8) and 109Cd
K XRF (50) methods. These relationships
allow the inference of the average blood
lead level over a defined working lifetime
from a single K XRF bone lead measure-
ment.
The possibility that skeletal lead stores
are eventually released has been the subject
of recent discussion (66-68). The concern
is that lifetime lead stores may act as an
endogenous source oflead exposure in later
life or during times of elevated bone
turnover, as occurs during pregnancy and
osteoporosis. Evidence to support the
hypothesis that skeletal lead can indeed act
as an endogenous source ofexposure comes
from a handful of K XRF studies (18,47,
51,62). A clear relationship can be seen
between blood lead and bone lead levels
observed in those no longer occupationally
exposed to lead. These studies have natural-
ly sought to quantify a characteristic half-
time for lead turnover in the bones studied.
The estimates have varied and have tended
to increase as more longitudinal data have
become available. The values that follow
can be compared to the frequently cited
value of 10,000 days (approximately 27.4
years) (69). Christoffersson et al. (62) stud-
ied eight subjects for 2-5 years immediately
after the end of their exposure and 6 sub-
jects 7-13 years after the end oflead expo-
sure. Mean half-times for the decrease of
phalanx lead levels were 7 years (range
3-15 years) in the former group and 8 years
(range 2-oo years) in the latter group.
Nilsson et al. (47) examined the same
group several years later. With the longer-
term data, the group of 14 workers yielded
an increased characteristic half-time of 16
years (95% CI: 12-23 years). Gerhardsson
et al. (51) evaluated half-times for tibia and
calcaneus of 27 years (95% CI: 16-98
years) and 16 years (95% CI: 11-29 years),
respectively. Erkkila et al. (18) did not give
quantitative half-time values but did find
evidence that bones ofpredominantly corti-
cal nature exhibit longer half-times.
Discussion and Conclusions
We suggest that in vivo measurements of
lead in bone will not, ultimately, replace
any existing measurements of lead expo-
sure. Rather, they will supplement the
existing tests by providing information on
lead pools that cannot be otherwise sam-
pled except by biopsy. A possible exception
is replacement ofthe provocative chelation
test with an L XRF measurement, if it is
confirmed that L XRF measurements do
indeed sample the relatively short-term lead
pool accessed byprovocative chelation.
The radiation doses for K and L meth-
ods are so low that they should not be a
deciding factor in whether to conduct a
study on any population. Improvements in
measurement system sensitivity should be
accompanied by evaluation of the dose. A
recent concern has been the possible inter-
ferences to the lead signal in an L XRF
measurement (70). For example, the pres-
ence of arsenic in the skin overlying the
measurement site could artificially inflate a
bone lead level reported with the L XRF
method. At present there is no empirical
evidence either to support or reject this
hypothesis. There are no suggested inter-
ferences present in the spectrum ofa 109Cd
KXRF measurement.
It is our opinion that further work is
not required to show that XRF constitutes
a promising technology. However, there
are further questions that should be ad-
dressed. First, all methods should be vali-
dated by an independent laboratory.
Validation should address the questions of
accuracy, precision, and volume of bone
sampled. Second, the replication of results
produced by the pioneering laboratory is
an important precursor to the widespread
acceptance of any new method by the
research community. Replication of the
109Cd and 57Co K XRF methods has
begun in several laboratories. Similar repli-
cation is required for the L XRF method.
Third, it is clear that K and L XRF mea-
surements do sample different bone vol-
umes, but the implications of this differ-
ence are not established. K and L XRF
measurements may yield different informa-
tion or they may yield slightly different
estimates of the same information. If dif-
ferent, K and L measurements may or may
not be complementary. Fourth, it is clear
that K XRF measurements relate strongly
to cumulative lead dose, the measurement
of which was the original motivation for
developing the method. It has yet to be
demonstrated that L XRF measurements
relate more strongly to a bioavailable lead
pool. Fifth, published data show that dif-
ferent bones have different turnover times.
More information on such parameters
would be useful in developing models for
the body's handling oflead and for testing
models already in existence.
Finally, two questions are often asked
by clinicians and epidemiologists: What
will be the detection limit for K XRF bone
lead measurements in children, and can
bone lead measurements be applied to
screening programs? There are no simple
answers to these questions. L XRF has
been applied to children, and this is an
obvious strength ofthe method. 109Cd K
XRF measurements have been performed
in a limited number ofchildren (24) with
no reported degradation in precision com-
pared to the precision of adult measure-
ments. Clearly, K XRF can be applied to
children but it is not intuitively obvious
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what precision would be obtained. In our
experience, it is likely that the precision of
measurements of children's bones will be
worse than the precision obtainable from
adult bones because the total amount of
bone mineral sampled will be less for chil-
dren. It is unlikely that the degradation in
precision would be by as much as a factor
oftwo. This would still make K XRF bone
lead measurements valuable in children.
With regard to screening, it is our opinion
that none of the XRF methods is suffi-
ciently developed to be applied in pro-
grams to screen the general population.
Some methods are more developed and
robust than others, but none is yet ready
for widespread application. Nevertheless,
bone lead measurements may prove to be,
in the future, a valuable screening and even
a diagnostic tool for the clinician.
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